Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19
Moderna (MRNA) announced that the U.S. Food and Drug Administration, FDA, has approved mNEXSPIKE, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' said Stephane Bancel, Chief Executive Officer of Moderna. 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.'
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
28 minutes ago
- The Hill
Trump administration rescinds emergency abortion guidance
The Trump administration has rescinded guidance telling health care workers who provide abortions to save their patients' lives that they are protected under federal law. The Department of Health and Human Services and the Centers for Medicare and Medicaid Services announced Tuesday that it is rescinding guidance issued during the Biden administration, reinforcing to hospitals that under the Emergency Medical Treatment & Labor Act (EMTALA) they must provide emergency abortions to pregnant patients if they are needed to save their lives. 'Legally, it means nothing,' Alexa Kolbi-Molinas, deputy director of the American Civil Liberties Union's Reproductive Freedom Project told The Hill. 'The obligation to provide emergency care comes from a federal statute… and as much as they might like to President Trump and Secretary Kennedy can not erase 40 years of law with this press release.' CMS said in a statement that the agency will continue to enforce EMTALA, which protects all emergency room patients seeking treatment, including 'identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy.' 'CMS will work to rectify any perceived legal confusion and instability created by the former administration's actions,' the statement adds. The guidance change comes about two months after the Trump administration dropped a high-profile case over the right to an emergency abortion in Idaho, which health care policy experts said signaled an 'imminent reversal' of EMTALA guidance issued by the Biden administration. EMTALA was passed in 1986 to protect Americans from 'patient dumping,' a practice at hospitals and other clinics where patients are transferred to other facilities without their consent due to their inability to pay. The Biden administration in 2022 issued guidance on abortion specifically, following the Supreme Court's Dobbs decision, which overturned Roe v. Wade. A cascade of state laws quickly banned abortion, but the guidance allowed for emergency procedures and protected physicians in those cases. The move does not change the law, but it does make it more confusing for doctors to know what care they can legally provide pregnancy terminations, especially if they practice in states with abortion bans, according to Kolbi-Molinas. Reproductive rights groups and health care providers are bashing the move, arguing that it will profoundly hurt the health of pregnant people in the United States. 'By rescinding this guidance, the Trump administration has sent a clear signal that it is siding not with the majority, but with its anti-abortion allies — and that will come at the expense of women's lives,' Kolbi-Molinas said. 'The ACLU will use every lever we have to keep President Trump and his administration from endangering our health and lives.' Jamila Perritt, president and CEO of the group Physicians for Reproductive Health, said that she is 'deeply troubled' by the Trump administration's decision to change the guidance, arguing that it is abandoning its responsibility to people who need emergency medical care. 'This action sends a clear message: the lives and health of pregnant people are not worth protecting,' she said in a statement. 'Complying with this law can mean the difference between life and death for pregnant people, forcing providers like me to choose between caring for someone in their time of need and turning my back on them to comply with cruel and dangerous laws…' Meanwhile, some anti-abortion groups lauded CMS's move, calling it a 'victory.' 'Led by Dr. Oz, the Trump administration has delivered another win for life and truth—stopping Biden's attack on emergency care for both pregnant moms and their unborn children,' wrote Marjorie Dannenfelser, president of the anti-abortion group Susan B. Anthony Pro-Life America. 'We call on more states to follow the Trump administration's lead and pass Med Ed laws to protect women from abortion lobby misinformation.'
Yahoo
29 minutes ago
- Yahoo
Why Guardant Health Stock Surged Nearly 9% Higher Today
The company's Shield multi-cancer detection test won an important designation from a top regulator. This should help bring it to market quicker. 10 stocks we like better than Guardant Health › Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%. This morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cancer detection (MCD) test its Breakthrough Device designation. This instantly confers a high status on Shield, as the FDA's designation is given only to a small clutch of medical devices that can either diagnose or treat a disease more effectively than other products. In Shield's case, it is quite a versatile diagnostic device that can screen for a wide range of cancers, including colorectal, lung, and ovarian. It is designed to evaluate people 45 years of age or older who are at a typical average risk for cancer. According to Guardant, Shield has 98.6% specificity and 75% sensitivity in detecting certain cancers. In its news release touting the FDA's move, Guardant quoted its co-CEO AmirAli Talasaz as saying that it "shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw." "We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly," he added. Another big plus of the Breakthrough Device designation is that it's part of an FDA initiative aimed at getting useful medical products to market faster. Talasaz and his team at Guardant might just get their wish with Shield before long. Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Guardant Health. The Motley Fool has a disclosure policy. Why Guardant Health Stock Surged Nearly 9% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Moderna agrees to true placebo-controlled trial of new COVID vaccine, Kennedy says
WASHINGTON (Reuters) -U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine. While noting that he was aware of concerns about the Food and Drug Administration's limited approval of the new mRNA vaccine for high-risk populations, Kennedy assured the agency will monitor and collect data throughout the trial for every adverse outcome.
